Rapport Therapeutics (NASDAQ:RAPP) Hits New 1-Year Low – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $16.51 and last traded at $16.67, with a volume of 22375 shares. The stock had previously closed at $17.79.

Rapport Therapeutics Price Performance

The firm has a 50 day moving average price of $21.21.

Institutional Trading of Rapport Therapeutics

Institutional investors have recently bought and sold shares of the business. Values First Advisors Inc. purchased a new stake in shares of Rapport Therapeutics during the third quarter worth about $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Rapport Therapeutics in the third quarter valued at approximately $34,000. JPMorgan Chase & Co. acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter worth $83,000. SG Americas Securities LLC purchased a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $101,000. Finally, Sandia Investment Management LP acquired a new stake in Rapport Therapeutics during the second quarter worth $116,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.